Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Accumulated Depreciation: 2020-2024

Historic Accumulated Depreciation for Janux Therapeutics (JANX) over the last 5 years, with Dec 2024 value amounting to $5.0 million.

  • Janux Therapeutics' Accumulated Depreciation rose 46.28% to $6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.5 million, marking a year-over-year increase of 46.28%. This contributed to the annual value of $5.0 million for FY2024, which is 69.94% up from last year.
  • According to the latest figures from FY2024, Janux Therapeutics' Accumulated Depreciation is $5.0 million, which was up 69.94% from $2.9 million recorded in FY2023.
  • In the past 5 years, Janux Therapeutics' Accumulated Depreciation registered a high of $5.0 million during FY2024, and its lowest value of $21,000 during FY2020.
  • Its 3-year average for Accumulated Depreciation is $2.9 million, with a median of $2.9 million in 2023.
  • Data for Janux Therapeutics' Accumulated Depreciation shows a peak YoY skyrocketed of 641.98% (in 2022) over the last 5 years.
  • Yearly analysis of 5 years shows Janux Therapeutics' Accumulated Depreciation stood at $21,000 in 2020, then skyrocketed by 523.81% to $131,000 in 2021, then skyrocketed by 641.98% to $972,000 in 2022, then spiked by 199.79% to $2.9 million in 2023, then skyrocketed by 69.94% to $5.0 million in 2024.